Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020

Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding the timeline of antibody decline is important for interpreting SARS-CoV-2 serology resu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:MMWR. Morbidity and mortality weekly report 2020-11, Vol.69 (47), p.1762-1766
Hauptverfasser: Self, Wesley H, Tenforde, Mark W, Stubblefield, William B, Feldstein, Leora R, Steingrub, Jay S, Shapiro, Nathan I, Ginde, Adit A, Prekker, Matthew E, Brown, Samuel M, Peltan, Ithan D, Gong, Michelle N, Aboodi, Michael S, Khan, Akram, Exline, Matthew C, Files, D Clark, Gibbs, Kevin W, Lindsell, Christopher J, Rice, Todd W, Jones, Ian D, Halasa, Natasha, Talbot, H Keipp, Grijalva, Carlos G, Casey, Jonathan D, Hager, David N, Qadir, Nida, Henning, Daniel J, Coughlin, Melissa M, Schiffer, Jarad, Semenova, Vera, Li, Han, Thornburg, Natalie J, Patel, Manish M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding the timeline of antibody decline is important for interpreting SARS-CoV-2 serology results. Serum specimens were collected from a convenience sample of frontline health care personnel at 13 hospitals and tested for antibodies to SARS-CoV-2 during April 3-June 19, 2020, and again approximately 60 days later to assess this timeline. The percentage of participants who experienced seroreversion, defined as an antibody signal-to-threshold ratio >1.0 at baseline and
ISSN:0149-2195
1545-861X
DOI:10.15585/MMWR.MM6947A2